The Ankylosing Spondylitis Market was valued at USD 5.77 billion in 2023, projected to reach USD 11.15 billion by 2032 with a CAGR of 7.59%. The U.S. market alone accounted for USD 2.67 billion in 2023 and is expected to double by 2032 at a CAGR of 7.33%.

Growth is driven by the global rise in ankylosing spondylitis cases, increased patient awareness, and advancements in biologic and biosimilar therapies revolutionizing treatment protocols.

The top players in the market include AbbVie, Pfizer, Novartis, Johnson & Johnson, and more, offering a range of treatments for ankylosing spondylitis.

Ankylosing Spondylitis Market Report Scope includes a CAGR of 7.59% from 2024 to 2032, with major players in North America and the Asia-Pacific region showing the fastest growth.

NSAIDs dominated the market in 2023 with a 48.1% share, providing cost-effective pain relief. The parenteral segment led in 2023, offering effective delivery of biologics and biosimilars.

Prescription drugs held the largest market share in 2023, providing faster and long-term symptom relief compared to OTC treatments, driven by advancements in biologic injectables and oral therapies. The Ankylosing Spondylitis Market Report offers unique selling propositions including Therapy Adoption & Patient Journey Mapping, Pricing, Reimbursement & Access Strategy Insight, Unmet Needs & Pipeline Differentiation Matrix, Physician Attitude & Behavior, RWE & Treatment Outcomes Insights, Market Access & Distribution Channel Assessment, and Regulatory & Policy Impact Assessment. Access the complete report details for in-depth analysis and outlook. Contact SNS Insider for more information or customization options. SNS Insider is a leading market research and consulting agency providing clients with current, accurate market data and insights to make informed decisions.

Read more at GlobeNewswire: Ankylosing Spondylitis Market Size to Hit USD 11.15 Billion